Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 854 of 6351
-
Adaptive radiation aims to outsmart aggressive brain tumors
Disease control OngoingThe goal of this study is to test whether an adaptive radiation therapy (RT), two-phase approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive, two-phase RT appro…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
A simple mail delivery could boost colorectal cancer screening rates
Prevention CompletedThis is a randomized controlled trial comparing the effect on participation rates to colorectal cancer screening between an intervention arm (invitation letter to the screening program including a FIT test with or without prior notification) and a control arm with the standard of…
Sponsor: International Agency for Research on Cancer • Aim: Prevention
Last updated Aug 28, 2026 00:00 UTC
-
Can a common anesthesia drug shield the brain after heart surgery?
Knowledge-focused CompletedThis observational study evaluated the association between intraoperative dexmedetomidine use and postoperative delirium (POD) in adults undergoing cardiac surgery with cardiopulmonary bypass (CPB). The study included two linked clinical components. First, routinely collected cli…
Sponsor: Shusheng Li • Aim: Knowledge-focused
Last updated Sep 10, 2026 08:00 UTC
-
New hope for young AML patients: drug cocktail targets resistant cancer
Disease control Recruiting nowThe investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill aims to slow Parkinson's in patients with genetic mutation
Disease control OngoingThe purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidas…
Phase 2 • Sponsor: Bial R&D Investments, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for breast cancer patients with brain tumors: experimental drug enters trial
Disease control Recruiting nowThis study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a cancer drug reboot the immune system after a stem cell transplant?
Disease control OngoingThe purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recove…
Phase 2 • Sponsor: Divaya Bhutani • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Experimental CAR t therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Phase 1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New triple therapy targets hard-to-treat ovarian cancer
Disease control OngoingImmunotherapy with immune checkpoint inhibitors, including pembrolizumab, have emerged as a promising option in several solid cancers with durable effect and low toxicity profile. However, the benefit is limited to smaller subset of solid tumors. This trial involves the enhanceme…
Phase 2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug cocktail aims to fight rare uterine cancer after chemo fails
Disease control OngoingThis phase II/III trial compares the effect of the combination treatment with olaparib and temozolomide to trabectedin or pazopanib (two of the most common chemotherapy drugs used as usual approach) in patients with uterine leiomyosarcoma that may have spread from where it first …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Stopped earlyThis is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy or with sintilimab in adult subjects with advanced and metastatic solid tumo…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take on three Hard-to-Treat cancers
Disease control PausedTo find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for tough blood cancers: venetoclax combo enters human trials
Disease control Recruiting nowThis trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute ly…
Phase 1 • Sponsor: Andrew E. Place, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Tough-to-Treat T-Cell lymphoma? pacritinib trial opens
Disease control Recruiting nowThe main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
A Needle-Free future for kids after heart transplants?
Knowledge-focused Recruiting nowAcute rejection remains a major cause of morbidity and mortality in pediatric patients after heart transplant. In order to screen for rejection, most centers perform heart catheterizations with endomyocardial biopsies frequently in the first year post transplant and then every 1-…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
New 24-Strain pneumonia vaccine shows promise in infant trial
Vaccine CompletedThe objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose…
Phase 2 • Sponsor: Vaxcyte, Inc. • Aim: Vaccine
Last updated Jun 26, 2026 16:37 UTC
-
New hope for kids with kidney disease: drug may cut relapses and steroids
Disease control OngoingThis open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged \>= 2-25 years) with frequently relapsing nephrotic syndro…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New short radiation course aims to stop returning prostate cancer
Disease control OngoingThe main objective of the trial is to explore the efficacy and safety of combining short-term androgen deprivation therapy (ADT) over 6 months to focal ultrahypofractionated salvage radiotherapy (SRT) delivered in 5 fractions to the site of local recurrence within the prostate be…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Massive east african trial aims to slash new HIV cases
Prevention CompletedThis study will evaluate the effects of optimized dynamic prevention and treatment packages delivered in a precision community health model on HIV incidence, as well as other health outcomes, in a community randomized trial design.
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
Could water pills be the key to protecting kidneys and hearts?
Disease control Recruiting nowChronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardi…
Phase 3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC